Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| non-classical monocyte | 13 studies | 28% ± 13% | |
| classical monocyte | 9 studies | 27% ± 9% | |
| macrophage | 7 studies | 24% ± 7% | |
| regulatory T cell | 7 studies | 18% ± 2% | |
| conventional dendritic cell | 6 studies | 30% ± 14% | |
| CD8-positive, alpha-beta T cell | 6 studies | 18% ± 3% | |
| CD4-positive, alpha-beta T cell | 5 studies | 19% ± 3% | |
| epithelial cell | 5 studies | 32% ± 11% | |
| CD4-positive, alpha-beta memory T cell | 4 studies | 19% ± 3% | |
| natural killer cell | 4 studies | 21% ± 2% | |
| endothelial cell | 4 studies | 23% ± 5% | |
| plasmacytoid dendritic cell | 4 studies | 21% ± 5% | |
| monocyte | 4 studies | 17% ± 1% | |
| CD8-positive, alpha-beta memory T cell | 3 studies | 18% ± 3% | |
| CD16-negative, CD56-bright natural killer cell, human | 3 studies | 19% ± 2% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 20% ± 3% | |
| myeloid cell | 3 studies | 23% ± 7% | |
| ciliated cell | 3 studies | 25% ± 3% | |
| type I pneumocyte | 3 studies | 21% ± 4% | |
| dendritic cell | 3 studies | 43% ± 11% | |
| effector memory CD4-positive, alpha-beta T cell | 3 studies | 18% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 2065.42 | 1445 / 1445 | 100% | 36.50 | 183 / 183 |
| intestine | 100% | 2800.21 | 966 / 966 | 100% | 47.77 | 527 / 527 |
| ovary | 100% | 1453.51 | 180 / 180 | 100% | 27.19 | 430 / 430 |
| pancreas | 100% | 1849.05 | 328 / 328 | 100% | 36.79 | 178 / 178 |
| stomach | 100% | 2661.25 | 359 / 359 | 100% | 45.66 | 286 / 286 |
| skin | 100% | 2579.80 | 1808 / 1809 | 100% | 40.81 | 472 / 472 |
| lung | 100% | 2916.32 | 577 / 578 | 100% | 43.10 | 1155 / 1155 |
| bladder | 100% | 2018.43 | 21 / 21 | 100% | 40.97 | 503 / 504 |
| prostate | 100% | 1968.38 | 245 / 245 | 100% | 37.46 | 501 / 502 |
| uterus | 100% | 1729.04 | 170 / 170 | 100% | 32.69 | 458 / 459 |
| thymus | 100% | 2514.10 | 653 / 653 | 100% | 33.17 | 603 / 605 |
| breast | 100% | 2728.49 | 459 / 459 | 100% | 34.64 | 1113 / 1118 |
| liver | 100% | 2240.04 | 226 / 226 | 99% | 32.54 | 403 / 406 |
| kidney | 100% | 2351.46 | 89 / 89 | 99% | 27.40 | 888 / 901 |
| adrenal gland | 100% | 2755.16 | 258 / 258 | 97% | 21.92 | 222 / 230 |
| brain | 96% | 1126.78 | 2534 / 2642 | 100% | 26.51 | 705 / 705 |
| adipose | 100% | 3029.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 36.66 | 29 / 29 |
| muscle | 100% | 3617.86 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 2815.05 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 34.74 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 15.54 | 1 / 1 |
| blood vessel | 100% | 2011.65 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 100% | 3252.60 | 925 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 99% | 32.91 | 79 / 80 |
| heart | 98% | 2856.72 | 845 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
| GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
| GO_0006355 | Biological process | regulation of DNA-templated transcription |
| GO_0045892 | Biological process | negative regulation of DNA-templated transcription |
| GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0000785 | Cellular component | chromatin |
| GO_0031965 | Cellular component | nuclear membrane |
| GO_0005634 | Cellular component | nucleus |
| GO_0003677 | Molecular function | DNA binding |
| GO_0042803 | Molecular function | protein homodimerization activity |
| GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
| GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
| GO_0001227 | Molecular function | DNA-binding transcription repressor activity, RNA polymerase II-specific |
| GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
| GO_1990837 | Molecular function | sequence-specific double-stranded DNA binding |
| GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
| GO_0003700 | Molecular function | DNA-binding transcription factor activity |
| GO_0046982 | Molecular function | protein heterodimerization activity |
| GO_0005515 | Molecular function | protein binding |
| Gene name | MLX |
| Protein name | MAX dimerization protein MLX Max-like protein X (Class D basic helix-loop-helix protein 13) (bHLHd13) (Max-like bHLHZip protein) (Protein BigMax) (Transcription factor-like protein 4) |
| Synonyms | BHLHD13 TCFL4 |
| Description | FUNCTION: Transcription regulator. Forms a sequence-specific DNA-binding protein complex with MAD1, MAD4, MNT, WBSCR14 and MLXIP which recognizes the core sequence 5'-CACGTG-3'. The TCFL4-MAD1, TCFL4-MAD4, TCFL4-WBSCR14 complexes are transcriptional repressors. Plays a role in transcriptional activation of glycolytic target genes. Involved in glucose-responsive gene regulation. . |
| Accessions | Q9UH92 ENST00000435881.7 [Q9UH92-3] ENST00000591024.1 K7EID0 ENST00000246912.8 [Q9UH92-1] ENST00000346833.8 [Q9UH92-2] |